Global Primary Care POC Diagnostics Market Size Study & Forecast, by Product (Infectious Diseases, Glucose Testing, Autoimmune Disease, Hb1Ac Testing, Fertility, Others), by End Use (Pharmacy & Retail Clinics, Physician Office, Urgent Care Clinics, Non-pr

Global Primary Care POC Diagnostics Market Size Study & Forecast, by Product (Infectious Diseases, Glucose Testing, Autoimmune Disease, Hb1Ac Testing, Fertility, Others), by End Use (Pharmacy & Retail Clinics, Physician Office, Urgent Care Clinics, Non-practice Clinics), and Regional Analysis, 2023-2030

Global Primary Care POC Diagnostics Market is valued at approximately USD 15.40 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2023-2030. Primary Care Point of Care (POC) Diagnostics encompasses medical diagnostic tests and devices conducted in close proximity to the patient, whether at a medical practitioner's office, clinic or even within a home setting, instead of centralized laboratory testing. These diagnostic tools are engineered to furnish swift and immediate results, empowering healthcare providers to promptly assess a patient's health status. They are frequently employed for standard testing, early disease screening, and continuous health condition monitoring. The Primary Care POC Diagnostics Market is expanding because of factors such as the growing need for quick diagnostic results in primary care settings, coupled with the rising prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and infectious diseases. Additionally, the swift development of Point-Of-Care Testing (POCT) presents significant growth opportunities for both primary and secondary care environments. Escalating healthcare costs in secondary and tertiary care has redirected the healthcare sector's focus towards primary care. A substantial reduction in these cost challenges can be achieved through routine early-stage patient screening in primary care. Consequently, this is expected to substantially propel market expansion.

In addition, the growing geriatric population is acting as a catalyzing factor for market growth across the globe. The aging people require more frequent healthcare interventions and monitoring, which drives the demand for POC diagnostic solutions. As per United Nations World Population Ageing Report of 2019, there were 703 million persons aged 65 years or over in the world in 2019. The number of aged persons is projected to double and reach 1.5 billion by 2050. POC diagnostics help to provide these individuals with the care they need in a convenient and timely manner. Thus, these aforementioned factors are propelling the growth of the Primary Care POC Diagnostics Market during the estimated period. Moreover, the rising advancement in POC products, as well as the increasing number of government initiatives to promote POC diagnostics present various lucrative opportunities over the forecast years. However, the unavailability of skilled personnel and the high cost of devices and consumables are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Primary Care POC Diagnostics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of major players offering products and services, government support, and a growing demand for these solutions in primary home healthcare and assisted healthcare settings. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The rise in the number of companies tapping into unexplored opportunities in the area is a contributing factor. Additionally, the increasing awareness among the population about the importance of early disease detection for enhancing patient survival rates is anticipated to significantly propel the market demand across the region.

Major market players included in this report are:
Roche Diagnostics
BD Biosciences
Danaher Corporation
Abbott Laboratories
Instrumentation Laboratory SpA
bioMerieux
Siemens Healthcare GmbH
Quidel Corporation
Bio-Rad Laboratories, Inc.
QIAGEN Corporation

Recent Developments in the Market:
 In April 2023, BioMerieux and Oxford Nanopore established a strategic collaboration to develop innovative diagnostic tools for infectious diseases.
 In June 2022, Roche Diagnostics unveiled the introduction of the BenchMark ULTRA PLUS cancer diagnostic tissue staining system. It boasts an enhanced workflow, increased diagnosis efficiency, and environmental sustainability.

Global Primary Care POC Diagnostics Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, End Use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Infectious Diseases
Glucose Testing
Autoimmune Disease
Hb1Ac Testing
Fertility
Others

By End Use:
Pharmacy & Retail Clinics
Physician Office
Urgent Care Clinics
Non-practice Clinics

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa


Companies Mentioned
Roche Diagnostics
BD Biosciences
Danaher Corporation
Abbott Laboratories
Instrumentation Laboratory SpA
bioMerieux
Siemens Healthcare GmbH
Quidel Corporation
Bio-Rad Laboratories, Inc.
QIAGEN Corporation

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.